Document Analysis NLP IA
FREQ, RAKE or TFIDF
Summary (IA Generated)
Working at the intersection of biology and computing may be the most exciting new spot for technologists at the moment.
It’s certainly been an incredible opportunity for Koller whose work now spans the development of treatments for potential neurological diseases and a nearer term research and development effort on hepatitis with Gilead Pharmaceuticals.
By synthesizing these two disciplines Koller’s company flips the process of drug discovery on its head, the company is designed sift through massive amounts of data to search for patterns in the expression of certain conditions.
Once those patterns are determined, the company can examine the pathways or mechanisms associated with that expression to determine targets for potential therapies.
“We now have massive amounts of data that is truly relevant to human disease,” Koller said.
The company can identify new patient segments, new interventions new drugs that may modulate the expression of those conditions.
There, Koller and her team were able to take a small, high-quality dataset from Gilead’s trials and identify how a disease progressed by looking at the patient data from different points in time.
“What we’re trying to do is so different and so out of alignment with how these companies do their work,” Koller said.
“ the notion of the innovator’s dilemma and coming in with a mindset that says we’re going to do this a completely different way,” said Koller.